# Mettler Toledo International Inc/: Form 10-Q for the period ended Sep 30, 2017

- Company: [Mettler Toledo International Inc/](/companies/mtd.md) (CIK 1037646)
- Form: 10-Q
- Filed: 2017-11-03
- Accepted by EDGAR: Nov 3, 2017, 09:35 ET
- Period: 2017-09-30
- Accession: 0001037646-17-000025
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1037646/000103764617000025/mtd10q93017.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1037646/000103764617000025/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-07-01 to 2017-09-30 | $698.8m | us-gaap:Revenues |
| Revenue | 9 months, 2017-01-01 to 2017-09-30 | $1.95bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2017-07-01 to 2017-09-30 | $217.2m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2017-01-01 to 2017-09-30 | $593.3m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2017-07-01 to 2017-09-30 | $400.3m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-01-01 to 2017-09-30 | $1.12bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-07-01 to 2017-09-30 | $32.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2017-01-01 to 2017-09-30 | $96.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2017-07-01 to 2017-09-30 | $204.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2017-01-01 to 2017-09-30 | $582.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2017-07-01 to 2017-09-30 | $8.2m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-01-01 to 2017-09-30 | $24.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-07-01 to 2017-09-30 | $34.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2017-01-01 to 2017-09-30 | $81.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-07-01 to 2017-09-30 | $105.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-01-01 to 2017-09-30 | $299.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-07-01 to 2017-09-30 | $3.99 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2017-01-01 to 2017-09-30 | $11.31 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-07-01 to 2017-09-30 | $4.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2017-01-01 to 2017-09-30 | $11.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-07-01 to 2017-09-30 | 26,303,529 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2017-01-01 to 2017-09-30 | 26,446,677 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2017-01-01 to 2017-09-30 | $351.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2017-01-01 to 2017-09-30 | $85.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2017-01-01 to 2017-09-30 | $335.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-09-30 | $169.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-09-30 | $986.6m | us-gaap:AssetsCurrent |
| Total assets | at 2017-09-30 | $2.50bn | us-gaap:Assets |
| Current liabilities | at 2017-09-30 | $652.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-09-30 | $1.98bn | us-gaap:Liabilities |
| Long-term debt | at 2017-09-30 | $1.05bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-09-30 | $18.5m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2017-09-30 | $513.0m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2017-09-30 | 25,579,124 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 32,338 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.*

### General

Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of the results to be expected for the full year ending December 31, 2017.

Changes in local currency exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.

We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.

### Results of Operations – Consolidated

The following tables set forth certain items from our interim consolidated statements of operations for the three and nine month periods ended September 30, 2017 and 2016 (amounts in thousands).

|  | Three months ended September 30, 2017 (unaudited)% |  | 2016 (unaudited)% |  | Nine months ended September 30, 2017 (unaudited)% |  | 2016 (unaudited)% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $698,799 | 100.0 | $650,598 | 100.0 | $1,947,022 | 100.0 | $1,798,558 | 100.0 |
| Cost of sales | 298,522 | 42.7 | 281,104 | 43.2 | 828,928 | 42.6 | 781,581 | 43.5 |
| Gross profit | 400,277 | 57.3 | 369,494 | 56.8 | 1,118,094 | 57.4 | 1,016,977 | 56.5 |
| Research and development | 32,477 | 4.6 | 30,139 | 4.6 | 96,723 | 5.0 | 89,813 | 5.0 |
| Selling, general and administrative | 204,915 | 29.3 | 187,680 | 28.8 | 582,604 | 29.9 | 544,399 | 30.3 |
| Amortization | 10,716 | 1.5 | 9,087 | 1.4 | 31,010 | 1.6 | 26,166 | 1.5 |
| Interest expense | 8,248 | 1.2 | 7,167 | 1.1 | 24,160 | 1.2 | 20,619 | 1.1 |
| Restructuring charges | 3,385 | 0.5 | 1,494 | 0.3 | 8,840 | 0.5 | 4,579 | 0.2 |
| Other charges (income), net | 909 | 0.2 | 603 | 0.1 | (5,565) | (0.3) | 8,492 | 0.5 |
| Earnings before taxes | 139,627 | 20.0 | 133,324 | 20.5 | 380,322 | 19.5 | 322,909 | 17.9 |
| Provision for taxes | 34,677 | 5.0 | 31,992 | 4.9 | 81,326 | 4.1 | 76,315 | 4.2 |
| Net earnings | $104,950 | 15.0 | $101,332 | 15.6 | $298,996 | 15.4 | $246,594 | 13.7 |

#### Net sales

Net sales were $698.8 million and $650.6 million for the three months ended September 30, 2017 and 2016, respectively, and $1.947 billion and $1.799 billion for the nine months ended September 30, 2017 and 2016. This represents an increase of 7% and 8% in U.S. dollars for the three and nine months ended September 30, 2017. Excluding the effect of currency exchange rate fluctuations, or in local currencies, net sales increased 6% and 9% for the three and nine months ended September 30, 2017. The Biotix and Troemner acquisitions contributed approximately 1% to our net sales for the three and nine months ended September 30, 2017. Global market conditions have generally been favorable during the first nine months of 2017 and we continue to benefit from the execution of our global sales and marketing programs. However, we remain cautious given the economic uncertainty that exists in certain regions of the world. We will also face difficult prior period comparisons during the fourth quarter of 2017 and especially as we enter 2018.

Net sales by geographic destination for the three and nine months ended September 30, 2017 in U.S. dollars increased in the Americas 2% and 8%, in Europe 7% and 5%, and in Asia/Rest of World 15% and 12%, respectively. Our net sales by geographic destination for the three and nine months ended September 30, 2017 in local currencies increased in the Americas 2% and 8%, in Europe 2% and 6%, and in Asia/Rest of World 15% and 13%, respectively. Our food retailing sales declined significantly in the third quarter due to very strong growth in the prior year and the timing of project activity. The decline in food retailing during the three months ended September 30, 2017 reduced local currency net sales in the Americas by 5% and Europe by 2%. The Biotix and Troemner acquisitions contributed approximately 2% to net sales in the Americas for the three and nine months ended September 30, 2017. A discussion of sales by operating segment is included below.

As described in Note 16 to our consolidated financial statements for the year ended December 31, 2016, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.

Net sales of products increased 7% in U.S. dollars and 6% in local currencies for the three months ended September 30, 2017 and increased 9% in U.S. dollars and 10% in local currencies for the nine months ended September 30, 2017. The Biotix and Troemner acquisitions contributed approximately 1% to our net sales of product for the three and nine months ended September 30, 2017. Service revenue (including spare parts) increased by 9% in U.S. dollars and 7% in local currencies for the three months ended September 30, 2017 and increased 7% in U.S. dollars and 7% in local currencies for the nine months ended September 30, 2017. The Troemner acquisition contributed approximately 1% to our net sales of service for the nine months ended September 30, 2017.

Net sales of our laboratory-related products, which represented approximately 49% of our total net sales, increased 10% in U.S. dollars and 9% in local currencies for the three months ended September 30, 2017, and increased 9% in U.S. dollars and 10% in local currencies for the nine months ended September 30, 2017. The local currency increase for the three and nine months ended September 30, 2017 included strong growth in most product categories. The Biotix and Troemner acquisitions also contributed approximately 2% to our net sales growth of laboratory-related products and services for the three and nine months ended September 30, 2017.

Net sales of our industrial-related products, which represented approximately 43% of our total net sales increased 10% in U.S. dollars and 8% in local currencies for the three months ended September 30, 2017 and increased 10% in U.S. dollars and 11% in local currencies for the nine months ended September 30, 2017. During the three and nine months ended September 30, 2017, we experienced strong growth in core-industrial and product inspection. Our core-industrial results include very strong results in China.

Net sales in our food retailing products, which represented approximately 8% of our total net sales decreased 16% in U.S. dollars and 18% in local currencies for the three months ended September 30, 2017, and decreased 5% in U.S. dollars and 4% in local currencies for the nine months ended September 30, 2017. The significant decline in net sales of our food retailing products is due to very strong growth in the prior year and the timing of project activity in the Americas and Europe for the three months ended September 30, 2017.

#### Gross profit

Gross profit as a percentage of net sales was 57.3% and 56.8% for the three months ended September 30, 2017 and 2016, respectively, and 57.4% and 56.5% for the nine months ended September 30, 2017 and 2016, respectively.

Gross profit as a percentage of net sales for products was 60.1% for both the three months ended September 30, 2017 and 2016, and 60.8% and 60.3% for the nine months ended September 30, 2017 and 2016, respectively.

Gross profit as a percentage of net sales for services (including spare parts) was 47.3% and 45.0% for the three months ended September 30, 2017 and 2016, respectively, and 45.5% and 43.5% for the nine months ended September 30, 2017 and 2016, respectively.

The increase in gross profit as a percentage of net sales for the three months ended September 30, 2017 includes favorable price realization and productivity gains offset in part by increased product costs and changes in foreign currency.

#### Research and development and selling, general and administrative expenses

Research and development expenses as a percentage of net sales was 4.6% for both the three months ended September 30, 2017 and 2016, and was 5.0% and for both the nine months ended September 30, 2017 and 2016. Research and development expenses increased 8% in U.S. dollars and increased 6% in local currencies for the three months ended September 30, 2017, and increased 8% in U.S. dollars and increased 9% in local currencies for the nine months ended September 30, 2017, respectively, compared to the corresponding periods in 2016 relating to increased investment in new product development.

Selling, general and administrative expenses as a percentage of net sales were 29.3% and 28.8% for the three months ended September 30, 2017 and 2016, respectively, and was 29.9% and 30.3% for the nine months ended September 30, 2017 and 2016. Selling, general and administrative expenses increased 9% in U.S. dollars and 8% in local currencies for the three months ended September 30, 2017, and increased 7% in U.S. dollars and 8% in local currencies for the nine months ended September 30, 2017, compared to the corresponding periods in 2016. The local currency increase includes investments in our field sales organization, higher cash incentive expense, and increased employee benefit costs.

#### Amortization, interest expense, other charges (income), net and taxes

Amortization expense was $10.7 million and $9.1 million for the three months ended September 30, 2017 and 2016, respectively, and $31.0 million and $26.2 million for the nine months ended September 30, 2017 and 2016, respectively.

Interest expense was $8.2 million and $7.2 million for the three months ended September 30, 2017 and 2016, respectively, and $24.2 million and $20.6 million for the nine months ended September 30, 2017 and 2016, respectively.

Other charges (income), net includes $1.7 million and $1.1 million of acquisition costs for the three and nine months ended September 30, 2017 and 2016, respectively. The nine months ended September 30, 2017 also includes a one-time gain of $3.4 million relating to the sale of a facility in Switzerland in connection with our initiative to consolidate certain Swiss operations into a new facility, while the nine months ended September 30, 2016 includes a one-time non-cash pension settlement charge of $8.2 million related to a lump sum offering to former employees of our U.S. pension plan. Other charges (income), net also includes (gains) losses from foreign currency transactions and hedging activities, interest income, and other items.

The provision for taxes is based upon using our projected annual effective tax rate of 22% before non-recurring discrete items for the three and nine month periods ended September 30, 2017.

The reduction in our estimated annual effective tax rate from 24% in 2016 to 22% in 2017, as well as our reported tax rate of 25% and 21% during the three and nine months ending September 30, 2017 is primarily related to our adoption of ASU 2016-09 pertaining to excess tax benefits associated with stock option exercises. Our 2017 estimated annual tax rate of 22% includes an estimated annual benefit of 2% related to the adoption of ASU 2016-09, the effects of which are being treated discretely each quarter. Our consolidated income tax rate is lower than the U.S. statutory rate primarily because of benefits from lower-taxed non-U.S. operations. The most significant of these lower-taxed operations are in Switzerland and China.

### Results of Operations – by Operating Segment

The following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 16 to our consolidated financial statements for the year ended December 31, 2016.

#### U.S. Operations (amounts in thousands)

|  | Three months ended September 30, |  | Nine months ended September 30, |  |
| --- | ---: | ---: | ---: | ---: |
|  | 2017 | 2016% | 2017 | 2016% |
| Total net sales | $263,408 | $255,866 3% | $763,097 | $702,502 9% |
| Net sales to external customers | $239,221 | $235,715 1% | $693,405 | $640,618 8% |
| Segment profit | $43,004 | $43,779 (2)% | $126,973 | $114,046 11% |

Total net sales and net sales to external customers increased 3% and 1% for the three months ended September 30, 2017 compared with the corresponding periods in 2016. Total net sales and net sales to external customers increased 9% and 8% for the nine months ended September 30, 2017 compared with the corresponding periods in 2016. The increase in total net sales and net sales to external customers for the three and nine months ended September 30, 2017 includes strong growth in product inspection and laboratory-related products offset in part by a significant decline in food retailing, which reduced net sales to external customers by 6% during the three months ended September 30, 2017. Net sales to external customers in our U.S. Operations also benefited approximately 2% and 3% from the Biotix and Troemner acquisitions for the three and nine months ended September 30, 2017.

Segment profit decreased $0.8 million and increased $12.9 million for the three and nine months ended September 30, 2017, respectively, compared to the corresponding periods in 2016. Our segment profit includes benefits from our margin expansion initiatives, offset in part by increased sales and service and research and development investments, as well as higher cash incentives and employee benefit costs. Our segment profit during the three months ended September 30, 2017 was also reduced by the significant net sales decline in food retailing.

#### Swiss Operations (amounts in thousands)

|  | Three months ended September 30, 2017 | 2016 | %1) | Nine months ended September 30, 2017 | 2016 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $170,883 | $159,959 | 7% | $491,816 | $464,938 | 6% |
| Net sales to external customers | $33,923 | $32,390 | 5% | $95,957 | $90,075 | 7% |
| Segment profit | $39,213 | $36,854 | 6% | $113,181 | $107,673 | 5% |

1\) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 7% in U.S. dollars and 5% in local currency for the three months ended September 30, 2017, compared to the corresponding periods in 2016, and increased 6% in both U.S. dollars and in local currency for the nine months ended September 30, 2017. Net sales to external customers increased 5% in U.S. dollars and 4% in local currency for the three months ended September 30, 2017 and increased 7% in both U.S. dollars and in local currency for the nine months ended September 30, 2017, compared to the corresponding periods in 2016. The increase in local currency net sales to external customers for the three and nine month periods ended September 30, 2017 includes solid growth in laboratory-related products and product inspection.

Segment profit increased $2.4 million and $5.5 million for the three and nine month periods ended September 30, 2017, respectively, compared to the corresponding periods in 2016. Segment profit during the three and nine months ended September 30, 2017 includes the impact of increased net sales and productivity improvements, offset by increased research and development activity, higher cash incentives costs and currency hedging gains in the prior year.

#### Western European Operations (amounts in thousands)

|  | Three months ended September 30, 2017 | 2016 | %1) | Nine months ended September 30, 2017 | 2016 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $212,009 | $202,841 | 5% | $597,318 | $572,248 | 4% |
| Net sales to external customers | $171,722 | $159,025 | 8% | $470,206 | $450,940 | 4% |
| Segment profit | $30,885 | $30,218 | 2% | $77,283 | $74,711 | 3% |

1\) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 5% in U.S. dollars and were flat in local currencies for the three months ended September 30, 2017 and increased 4% in U.S. dollars and 6% in local currencies for the nine months ended September 30, 2017, compared to the corresponding periods in 2016. Net sales to external customers increased 8% in U.S. dollars and 3% in local currencies for the three months ended September 30, 2017, and increased 4% in U.S. dollars and 6% in local currencies for the nine months ended September 30, 2017, compared to the corresponding periods in 2016. Local currency net sales to external customers for the three months ended September 30, 2017 includes solid growth in laboratory-related products and core-industrial, offset in part by a decrease in food retailing, which reduced net sales to external customers by 2%.

Segment profit increased $0.7 million and $2.6 million for the three and nine month periods ended September 30, 2017, respectively, compared to the corresponding periods in 2016. The increase in segment profit for the nine months ended September 30, 2017 includes benefits from our margin expansion initiatives and favorable currency translation, offset in part by increased sales and service investments and higher cash incentive costs.

#### Chinese Operations (amounts in thousands)

|  | Three months ended September 30, 2017 | 2016 | %1) | Nine months ended September 30, 2017 | 2016 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $193,692 | $161,717 | 20% | $502,533 | $444,130 | 13% |
| Net sales to external customers | $125,067 | $99,349 | 26% | $323,940 | $277,182 | 17% |
| Segment profit | $69,086 | $51,669 | 34% | $167,873 | $134,229 | 25% |

1\) Represents U.S. dollar growth for net sales and segment profit.

Total net sales increased 20% in both U.S. dollars and in local currency for the three months ended September 30, 2017 and increased 13% in U.S. dollars and 17% local currency for the nine months ended September 30, 2017, compared to the corresponding periods in 2016. Net sales to external customers increased 26% in both U.S. dollars and in local currency for the three months ended September 30, 2017 and increased 17% in U.S. dollars and 20% local currency during the nine months ended September 30, 2017, compared to the corresponding periods in 2016. The increase in local currency net sales to external customers during the three and nine months ended September 30, 2017 reflects very strong growth in most product categories. Our Chinese performance reflects a good economic environment with customers catching-up on their product replacement cycles, as well as our ability to shift resources towards faster growing markets. While

Chinese market conditions have improved, uncertainty remains, particularly in industrial markets. We will also face more difficult prior period comparisons during the remainder of the year and expect local currency net sales growth will be lower during the fourth quarter of 2017 than our year-to-date results.

Segment profit increased $17.4 million and $33.6 million for the three and nine month periods ended September 30, 2017, respectively, compared to the corresponding periods in 2016. The increase in segment profit for the three and nine months ended September 30, 2017 includes increased local currency net sales volume, benefits from our margin expansion and cost savings initiatives, and inter-segment transfers.

#### Other (amounts in thousands)

|  | Three months ended September 30, 2017 | 2016 | %1) | Nine months ended September 30, 2017 | 2016 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $130,620 | $125,889 | 4% | $368,995 | $344,567 | 7% |
| Net sales to external customers | $128,866 | $124,119 | 4% | $363,514 | $339,743 | 7% |
| Segment profit | $16,776 | $16,721 | —% | $45,106 | $41,064 | 10% |

1\) Represents U.S. dollar growth for net sales and segment profit.

Total net sales and net sales to external customers increased 4% in U.S. dollars and 2% in local currencies for the three months ended September 30, 2017 and increased both 7% in U.S. dollars and in local currencies for the nine months ended September 30, 2017 compared to the corresponding periods in 2016. Local currency net sales during the three months ended September 30, 2017 faced particularly difficult prior period comparisons.

Segment profit increased $0.1 million and $4.0 million for the three and nine months ended September 30, 2017, respectively, compared to the corresponding periods in 2016. Segment profit includes benefits from increased net sales, offset in part by sales and service investments, particularly during the three months ended September 30, 2017.

### Liquidity and Capital Resources

Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing. Currently, our financing requirements are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.

Cash provided by operating activities totaled $351.2 million during the nine months ended September 30, 2017, compared to $307.3 million in the corresponding period in 2016. The increase in 2017 is primarily related to higher net earnings.

Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $85.8 million for the nine months ended September 30, 2017 compared to $51.2 million in the corresponding period in 2016. The increase is primarily related to investments in manufacturing facilities. Cash flows from investing activities for the nine months ended September 30, 2017, also includes proceeds of $9.9 million relating to the sale of a facility in Switzerland in connection with our initiative to consolidate certain Swiss operations into a new facility. We expect to make net investments in new or expanded manufacturing facilities of $50 million to $60 million over the next two years.

We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness. In September 2017, we acquired the shares of Biotix, Inc., a manufacturer and distributor of plastic consumables associated with pipettes, including tips, tubes and reagent reservoirs used in the life sciences market based in the United States. The initial cash payment was $105 million and we may be required to pay additional cash consideration up to a maximum amount of $65 million based upon earnings thresholds in 2018 and 2019. The fair value of the contingent consideration obligation of $30.7 million relating to the Biotix acquisition was determined using a Monte Carlo simulation based on the our forecast of future results. Goodwill recorded in connection with the acquisition totaled $51.3 million, which is included in the our U.S. Operations segment. The fair value of the contingent consideration was determined using a Monte Carlo simulation. Identified intangible finite life assets acquired include customer relationships of $49.5 million, technology and patents of $8.0 million, indefinite life tradenames of $7.1 million, and other intangibles of $0.6 million. The identifiable finite life intangible assets will be amortized on a straight-line basis over periods ranging from 5 year to 18 years and the annual aggregate amortization expense is estimated at $3.7 million. Net tangible assets acquired were $19.2 million and recorded at fair value in the consolidated financial statements.

In 2017, we also incurred additional acquisition payments totaling $3.8 million. Goodwill recorded in connection with acquisitions totaled $0.3 million. The Company also recorded $3.1 million of identified intangibles primarily pertaining to technology and patents in connection with these acquisitions, which will be amortized on a straight-line basis over 12 years. Net tangible assets acquired were $0.2 million and recorded a fair value in the consolidated financial statements.

We plan to repatriate earnings from China, Switzerland, Germany, the United Kingdom and certain other countries in future years and expect the only additional cost associated with the repatriation of such earnings outside the United States will be any applicable withholding taxes. All other undistributed earnings are considered to be permanently reinvested. As of September 30, 2017, we have an immaterial amount of cash and cash equivalents outside the United States where undistributed earnings are considered permanently reinvested. Accordingly, we believe the tax impact associated with repatriating our undistributed foreign earnings will not have a material effect on our liquidity.

#### Senior Notes and Credit Facility Agreement

Our debt consisted of the following at September 30, 2017:

|  | September 30, 2017 U.S. Dollar | Other Principal Trading Currencies | Total |
| --- | ---: | ---: | ---: |
| 3.67% $50 million Senior Notes due December 17, 2022 | 50,000 | — | 50,000 |
| 4.10% $50 million Senior Notes due September 19, 2023 | 50,000 | — | 50,000 |
| 3.84% $125 million Senior Notes due September 19, 2024 | 125,000 | — | 125,000 |
| 4.24% $125 million Senior Notes due June 25, 2025 | 125,000 | — | 125,000 |
| 1.47% EUR 125 million Senior Notes due June 17, 2030 | — | 146,956 | 146,956 |
| Debt issuance costs, net | (1,125) | (364) | (1,489) |
| Total Senior Notes | 348,875 | 146,592 | 495,467 |
| $800 million Credit Agreement, interest at LIBOR plus 87.5 basis points | 537,304 | 17,910 | 555,214 |
| Other local arrangements | — | 18,533 | 18,533 |
| Total debt | 886,179 | 183,035 | 1,069,214 |
| Less: current portion | — | (18,533) | (18,533) |
| Total long-term debt | $886,179 | $164,502 | $1,050,681 |

As of September 30, 2017, approximately $238.6 million was available under our Credit Agreement. During the three months ended September 30, 2017, we increased our borrowing under the Credit Agreement by $97.9 million, which primarily was used to fund the Biotix acquisition as described in Note 3. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates.

We currently believe that cash flow from operating activities, together with liquidity available under our credit facility and local working capital facilities, will be sufficient to fund currently anticipated working capital needs and capital spending requirements for the foreseeable future.

#### Share Repurchase Program

The Company has a share repurchase program of which there was $648.4 million of common shares remaining to be repurchased under the program as of September 30, 2017. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and existing cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and market conditions, the stock price, trading restrictions, the level of acquisition activity and other factors.

We have purchased 26.6 million shares since the inception of the program through September 30, 2017. During the nine months ended September 30, 2017 and 2016, we spent $335.0 million and $375.0 million on the repurchase of 647,756 and 1,048,075 shares at an average price per share of $517.15 and $357.77, respectively. We also reissued 206,646 shares and 193,517 shares held in treasury for the exercise of stock options and restricted stock units during the nine months ended September 30, 2017 and 2016, respectively.

### Effect of Currency on Results of Operations

Our earnings are affected by changing exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings go down. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also go down. We estimate a 1% strengthening of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.4 million to $1.6 million annually.

We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese Renminbi. The impact on our earnings before tax of the Chinese Renminbi weakening 1% against the U.S. dollar is a reduction of approximately $0.3 million to $0.5 million annually.

In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar and the Euro. Based on our outstanding debt at September 30, 2017, we estimate that a 10% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $20.4 million in the reported U.S. dollar value of our debt.

### Forward-Looking Statements Disclaimer

*You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties. You can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue”.*

*We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, planned research and development efforts and product introductions, adequacy of facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, customer demand, our competitive position , capital expenditures, cash flow, tax-related matters, compliance with laws, and effects of acquisitions.*

*Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2016 Annual Report on Form 10-K.*

## Market risk

As filed, 178 characters.

As of September 30, 2017, there was no material change in the information provided under Item 7A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

## Controls and procedures

As filed, 781 characters.

Under the supervision and with the participation of our management, including the Chief Executive Officer, Principal Financial Officer and the Principal Accounting Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer, Principal Financial Officer, and Principal Accounting Officer, have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 204 characters.

For the nine months ended September 30, 2017 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Filed Nov 3, 2017.
Source: SEC EDGAR, the filing index for accession 0001037646-17-000025. Last ingested by Listed: Nov 13, 2026, 02:43 ET. No prices; not investment advice.
